Genetics can be intricate, no doubt. With millions of mutations present in every human, one might wonder why not everyone is impacted by pathogenic diseases. The Patient Empowerment Program aims to assist you in grasping the fundamental concepts of various mutations and how they function, paving the way for you to enhance your understanding of genetics. Delve into the diverse array of disease-causing mutations, their characteristics, and explore which mutations could potentially be addressed through ASO treatment in this concluding episode of Advanced Genetics.
On This Episode We Discuss:
<ul><li>The nature of a SNP</li>
<li>Pre-mature-m-RNA effects</li>
<li>Indels can disrupt the reading frame</li>
<li>Defining Alleles, Homozygous, Heterozygous, and Compound Heterozygous</li>
<li>The difference between whole exome and genome sequencing</li>
<li>How we, at n-Lorem, decide which patients are amendable to ASO treatments</li>
<li>How we design ASOs to take advantage of different post-RNA binding mechanisms</li>
<li>Mechanisms: Non-allele selective RNAse H1, Allele-selective RNAse H1, and Splicing ASOs</li>
</ul>

Genetics can be intricate, no doubt. With millions of mutations present in every human, one might wonder why not everyone is impacted by pathogenic diseases. The Patient Empowerment Program aims to assist you in grasping the fundamental concepts of various mutations and how they function, paving the way for you to enhance your understanding of genetics. Delve into the diverse array of disease-causing mutations, their characteristics, and explore which mutations could potentially be addressed through ASO treatment in this concluding episode of Advanced Genetics. On This Episode We Discuss: The nature of a SNP Pre-mature-m-RNA effects Indels can disrupt the reading frame Defining Alleles, Homozygous, Heterozygous, and Compound Heterozygous The difference between whole exome and genome sequencing How we, at n-Lorem, decide which patients are amendable to ASO treatments How we design ASOs to take advantage of different post-RNA binding mechanisms Mechanisms: Non-allele selective RNAse H1, Allele-selective RNAse H1, and Splicing ASOs

Advanced Genetics Part 2

Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life. 

n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. 

The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crroke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Kim Butler, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.

Science

Medicine

Health & Fitness

Education

Life Sciences

Join the nano-rare disease community! Interviews features leading physicians, scientists, biotech experts, and patient advocates. Lessons teach core concepts about drugs. Our host Dr. Crooke has led the creation of antisense technology and his foundation, n-Lorem, is using this powerful technology to discover, develop, and provide personalized experimental antisense oligonucleotide medicines to nano-rare patients for free, for life. n-Lorem is a non-profit organization established to apply the efficiency, versatility and specificity of antisense technology to charitably provide experimental antisense oligonucleotide (ASO) medicines to treat patients (less than 30 patients) that are the result of a single genetic defect unique to only one or very few individuals. The advantage of experimental ASO medicines is that they can be developed rapidly, inexpensively and are highly specific. n-Lorem was founded by Dr. Stan Crooke, who founded IONIS Pharmaceuticals in 1989 and, through his vision and leadership, established the company as the leader in RNA-targeted therapeutics. The podcast is produced by n-Lorem Foundation and hosted by Dr. Stanley T. Crroke, who is the Founder, CEO and Chairman. Our videographer is Jon Magnuson. Our producers are Kira Dineen, Jon Magnuson, Kim Butler, and Amy Williford. To learn more about n-Lorem, visit nlorem.org. Contact us at podcast@nlorem.org.

Share Advanced Genetics Part 2

Sign up to save your podcasts

Advanced Genetics Part 2

Advanced Genetics Part 2

More shows like Patient Empowerment Program: A Rare Disease Podcast

This American Life

Embedded

The Daily

Crime Junkie

The Readout Loud

The Weekly Show with Jon Stewart

BioSpace